Wall Street rolled to more records on Thursday as Nvidia and Intel led a rally for technology stocks after announcing a deal that includes a $5 billion investment.

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred ...

Novo Nordisk (NYSE: NVO) -- the original Ozempic stock -- jumped higher again Thursday after announcing results from a weight ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Pharmaceutical companies are racing to develop a GLP-1 weight-loss drug in pill form. Novo Nordisk says its oral semaglutide pill led to "significant weight loss" in a trial.

Roughly one out of every two people who start taking semaglutide (Wegovy; Novo Nordisk) to lose weight will stop taking the medication within a year, according to a large population-based study out of ...

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

GLP-1 therapies not only aid weight loss but also reduce intrusive food thoughts and shift taste perception, which may ...

Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ...